Ken Fujise Selected Research

morelloflavone

1/2012	Morelloflavone, a biflavonoid inhibitor of migration-related kinases, ameliorates atherosclerosis in mice.
1/2009	Morelloflavone, a biflavonoid, inhibits tumor angiogenesis by targeting rho GTPases and extracellular signal-regulated kinase signaling pathways.
1/2009	Morelloflavone blocks injury-induced neointimal formation by inhibiting vascular smooth muscle cell migration.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ken Fujise Research Topics

Disease

6	Atherosclerosis 01/2022 - 07/2003
4	Neoplasms (Cancer) 12/2014 - 01/2009
2	Heart Arrest (Cardiac Arrest) 01/2022 - 09/2012
2	Coronary Artery Disease (Coronary Atherosclerosis) 09/2012 - 11/2011
2	Carcinogenesis 09/2011 - 01/2009
1	Lung Diseases (Lung Disease) 01/2022
1	Abdominal Aortic Aneurysm 01/2022
1	Vascular Diseases (Vascular Disease) 01/2022
1	Inflammation (Inflammations) 01/2022
1	Stroke (Strokes) 06/2020
1	Acute Coronary Syndrome 01/2019
1	Tics (Tic) 01/2019
1	Metabolic Diseases (Metabolic Disease) 02/2018
1	Type 2 Diabetes Mellitus (MODY) 02/2018
1	Hypertension (High Blood Pressure) 02/2018
1	Vascular Dementia (Subcortical Arteriosclerotic Encephalopathy) 02/2018
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 02/2018
1	Obesity 01/2017
1	Aneurysm (Aneurysms) 12/2012
1	Chest Pain (Chest Pains) 12/2012
1	ST Elevation Myocardial Infarction 12/2012
1	Heart Failure 01/2012
1	Prostatic Neoplasms (Prostate Cancer) 01/2009
1	Neoplasm Metastasis (Metastasis) 01/2009
1	Wounds and Injuries (Trauma) 01/2009
1	Hyperplasia 01/2009
1	Neointima 05/2008
1	Leukemia 10/2002

Drug/Important Bio-Agent (IBA)

3	morelloflavoneIBA 01/2012 - 01/2009
3	Tumor Suppressor Protein p53IBA 11/2011 - 07/2003
2	CholesterolIBA 01/2022 - 11/2013
2	Apoptosis Regulatory ProteinsIBA 01/2022 - 10/2002
2	BiflavonoidsIBA 01/2012 - 01/2009
2	Proteins (Proteins, Gene)FDA Link 11/2011 - 10/2002
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2022
1	LDL CholesterolIBA 01/2022
1	Pharmaceutical PreparationsIBA 01/2022
1	Prostaglandin D2IBA 01/2022
1	SolutionsIBA 01/2022
1	ProstaglandinsIBA 01/2022
1	A-factor (Streptomyces)IBA 01/2022
1	prostaglandin D2 receptorIBA 01/2022
1	Purinergic P2Y ReceptorsIBA 01/2019
1	Aryldialkylphosphatase (Paraoxonase)IBA 01/2019
1	TicagrelorIBA 01/2019
1	Clopidogrel (Plavix)FDA Link 01/2019
1	HDL CholesterolIBA 02/2018
1	Insulin (Novolin)FDA Link 01/2017
1	LipidsIBA 11/2013
1	LDL Receptors (LDL Receptor)IBA 11/2013
1	APOBEC-1 DeaminaseIBA 11/2013
1	Troponin IIBA 12/2012
1	Sirolimus (Rapamycin)FDA Link 12/2012
1	Mineralocorticoid Receptors (Mineralocorticoid Receptor)IBA 01/2012
1	Phosphotransferases (Kinase)IBA 01/2012
1	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 01/2012
1	Mineralocorticoid Receptor AntagonistsIBA 01/2012
1	DNA (Deoxyribonucleic Acid)IBA 11/2011
1	Peptides (Polypeptides)IBA 09/2011
1	AcidsIBA 09/2011
1	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 01/2009
1	GTP Phosphohydrolases (GTPases)IBA 01/2009
1	rho GTP-Binding Proteins (rho GTP-Binding Protein)IBA 01/2009
1	Bromodeoxyuridine (BrdU)IBA 05/2008
1	DNA Nucleotidylexotransferase (Terminal Deoxynucleotidyl Transferase)IBA 05/2008
1	DeoxyuridineIBA 05/2008

Therapy/Procedure

2	Therapeutics 01/2012 - 09/2011
1	Induced Hypothermia 01/2022
1	Renal Dialysis (Hemodialysis) 06/2020
1	Hepatectomy 01/2017
1	Radiotherapy 12/2014
1	Stents 12/2012
1	Ligation 12/2012
1	Coronary Artery Bypass (Coronary Artery Bypass Surgery) 12/2012
1	Heart-Assist Devices 09/2012